Cite
Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response.
MLA
Montecucco, Fabrizio, et al. “Treatment with KLEPTOSE® CRYSMEB Reduces Mouse Atherogenesis by Impacting on Lipid Profile and Th1 Lymphocyte Response.” Vascular Pharmacology, vol. 72, Sept. 2015, pp. 197–208. EBSCOhost, https://doi.org/10.1016/j.vph.2015.04.008.
APA
Montecucco, F., Lenglet, S., Carbone, F., Boero, S., Pelli, G., Burger, F., Roth, A., Bertolotto, M., Nencioni, A., Cea, M., Dallegri, F., Fraga-Silva, R. A., Fougère, L., Elfakir, C., Gassner, A.-L., Rudaz, S., Parissaux, X., Wils, D., Salomé, M., … Mach, F. (2015). Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. Vascular Pharmacology, 72, 197–208. https://doi.org/10.1016/j.vph.2015.04.008
Chicago
Montecucco, Fabrizio, Sébastien Lenglet, Federico Carbone, Silvia Boero, Graziano Pelli, Fabienne Burger, Aline Roth, et al. 2015. “Treatment with KLEPTOSE® CRYSMEB Reduces Mouse Atherogenesis by Impacting on Lipid Profile and Th1 Lymphocyte Response.” Vascular Pharmacology 72 (September): 197–208. doi:10.1016/j.vph.2015.04.008.